| scholarly article | Q13442814 |
| P50 | author | Donna H. Ryan | Q37368139 |
| Caroline M. Apovian | Q54032792 | ||
| P2093 | author name string | W Timothy Garvey | |
| P2860 | cites work | Screening for and Management of Obesity in Adults: U.S. Preventive Services Task Force Recommendation Statement | Q22241131 |
| Body-Mass Index and Mortality among 1.46 Million White Adults | Q22250878 | ||
| Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 | ||
| The medical care costs of obesity: An instrumental variables approach | Q22252387 | ||
| Long-term drug treatment for obesity: a systematic and clinical review | Q22253010 | ||
| Surgery for weight loss in adults | Q24194419 | ||
| 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study | Q24633604 | ||
| Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date | Q27014110 | ||
| Association of an intensive lifestyle intervention with remission of type 2 diabetes | Q27347992 | ||
| American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015 | Q28384855 | ||
| Prevalence of childhood and adult obesity in the United States, 2011-2012 | Q29547370 | ||
| Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes | Q30496725 | ||
| Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial | Q30539603 | ||
| Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study | Q30569749 | ||
| Adherence to a smartphone application for weight loss compared to website and paper diary: pilot randomized controlled trial | Q33439594 | ||
| Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes | Q33746480 | ||
| Comparative effectiveness of weight-loss interventions in clinical practice | Q33819180 | ||
| Live long and prosper: potentials of low-cost consumer devices for the prevention of cardiovascular diseases | Q33855338 | ||
| A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study | Q33888204 | ||
| The medical risks of obesity | Q33888248 | ||
| New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach | Q33938171 | ||
| XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients | Q33974818 | ||
| Prevention, recognition, and management of serotonin syndrome. | Q34022246 | ||
| A proposed clinical staging system for obesity | Q37384280 | ||
| The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity | Q37399447 | ||
| Are health behavior change interventions that use online social networks effective? A systematic review | Q37605878 | ||
| Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity | Q37640474 | ||
| Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. | Q38007964 | ||
| Assessment and lifestyle management of patients with obesity: clinical recommendations from systematic reviews | Q38245556 | ||
| Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study | Q38449189 | ||
| The impact of an online social network with wireless monitoring devices on physical activity and weight loss | Q44552722 | ||
| Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults | Q44856642 | ||
| Improving weight maintenance using virtual reality (Second Life). | Q45961338 | ||
| American association of clinical endocrinologists and american college of endocrinology consensus conference on obesity: building an evidence base for comprehensive action. | Q45984113 | ||
| Weight-loss maintenance for 10 years in the National Weight Control Registry | Q46719593 | ||
| Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study | Q47263791 | ||
| The FDA's assessment of two drugs for chronic weight management | Q47279989 | ||
| Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group | Q47284487 | ||
| Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study | Q47308250 | ||
| What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes | Q47314485 | ||
| Economic evaluation of weight loss interventions in overweight and obese women. | Q47328656 | ||
| Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial | Q47381748 | ||
| Pharmacological management of obesity: an endocrine Society clinical practice guideline | Q48134469 | ||
| AACE/ACE comprehensive diabetes management algorithm 2015. | Q50931076 | ||
| Addiction potential of phentermine prescribed during long-term treatment of obesity. | Q52302722 | ||
| American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. | Q54307680 | ||
| Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Soc | Q55668670 | ||
| 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults | Q61985181 | ||
| Collaborative management of chronic illness | Q73976742 | ||
| Contrave--a combination of bupropion and naltrexone for weight loss | Q85913811 | ||
| Validity of consumer-based physical activity monitors | Q87774016 | ||
| Intensive lifestyle intervention reduces urinary incontinence in overweight/obese men with type 2 diabetes: results from the Look AHEAD trial | Q34047087 | ||
| A complications-based clinical staging of obesity to guide treatment modality and intensity | Q34070626 | ||
| American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary | Q34081331 | ||
| Metabolic syndrome in healthy obese, overweight, and normal weight individuals: the Atherosclerosis Risk in Communities Study | Q34221548 | ||
| Obesity and severe obesity forecasts through 2030. | Q34275955 | ||
| The defence of body weight: a physiological basis for weight regain after weight loss | Q34309977 | ||
| Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis | Q34389317 | ||
| Multicenter, placebo-controlled trial of lorcaserin for weight management | Q34660152 | ||
| Will all Americans become overweight or obese? estimating the progression and cost of the US obesity epidemic | Q34811626 | ||
| Internet delivered behavioral obesity treatment | Q35003616 | ||
| Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials | Q35024182 | ||
| Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes | Q35060170 | ||
| Comparing behavioral weight loss modalities: incremental cost-effectiveness of an internet-based versus an in-person condition | Q35109439 | ||
| Four-year weight losses in the Look AHEAD study: factors associated with long-term success | Q35242207 | ||
| Effect of weight loss with lifestyle intervention on risk of diabetes | Q35568884 | ||
| Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study | Q35677262 | ||
| Peptides and their potential role in the treatment of diabetes and obesity | Q35760298 | ||
| Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy | Q35855817 | ||
| Efficacy of lifestyle modification for long-term weight control | Q36027621 | ||
| Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide | Q36028436 | ||
| Cluster analysis of the national weight control registry to identify distinct subgroups maintaining successful weight loss | Q36035910 | ||
| Low/no calorie sweetened beverage consumption in the National Weight Control Registry | Q36047523 | ||
| Use of topiramate in pregnancy and risk of oral clefts | Q36356810 | ||
| The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it | Q36541352 | ||
| Patterns of weight change associated with long-term weight change and cardiovascular disease risk factors in the Look AHEAD Study | Q36784472 | ||
| Website usage and weight loss in a free commercial online weight loss program: retrospective cohort study | Q36794773 | ||
| Achieving weight and activity goals among diabetes prevention program lifestyle participants | Q36825741 | ||
| Weight-loss maintenance in successful weight losers: surgical vs non-surgical methods | Q37057926 | ||
| American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease | Q37129163 | ||
| Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial | Q37151277 | ||
| Effect of intensive lifestyle intervention on sexual dysfunction in women with type 2 diabetes: results from an ancillary Look AHEAD study | Q37193515 | ||
| One-year weight losses in the Look AHEAD study: factors associated with success | Q37212232 | ||
| Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes | Q37250961 | ||
| Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity | Q37337828 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | obesity | Q12174 |
| human nutrition | Q2602563 | ||
| P304 | page(s) | S1-S26 | |
| P577 | publication date | 2015-07-01 | |
| P1433 | published in | Obesity | Q15763232 |
| P1476 | title | Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies | |
| P478 | volume | 23 Suppl 2 |
| Q91877515 | An Evidence-Based Approach to Teaching Obesity Management to Medical Students |
| Q47182659 | Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines |
| Q64294684 | Development and Validation of a Questionnaire Assessing Knowledge, Attitude, and Practices about Obesity among Obese Individuals |
| Q89885747 | Effectiveness of mindfulness based cognitive therapy on weight loss, improvement of hypertension and attentional bias to eating cues in overweight people |
| Q36413002 | Effects of bariatric surgery on pelvic floor disorders in obese women: a meta-analysis |
| Q39451553 | GLP-1/glucagon receptor co-agonism for treatment of obesity. |
| Q39429642 | Medical devices for the treatment of obesity |
| Q95270862 | Metabolic Syndrome and Cognitive Functions in Schizophrenia-Implementation of Dietary Intervention |
| Q38672477 | Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes |
| Q57176979 | New Insights about How to Make an Intervention in Children and Adolescents with Metabolic Syndrome: Diet, Exercise vs. Changes in Body Composition. A Systematic Review of RCT |
| Q59793710 | One-year weight management lowers lipopolysaccharide-binding protein and its implication in metainflammation and liver fibrosis |
| Q37469680 | Piperine's mitigation of obesity and diabetes can be explained by its up-regulation of the metabolic rate of resting muscle. |
| Q55245154 | The Gut Microbiome as a Target for the Treatment of Type 2 Diabetes. |
| Q28088815 | Weight Loss Pharmacotherapy: Brief Summary of the Clinical Literature and Comments on Racial Differences |
| Q58578732 | [Is the individual motivational interviewing effective in overweight and obesity treatment? A systematic review] |
Search more.